Erectile Dysfunction Clinical Trial
Official title:
Evaluate the Safety and Feasibility of Injecting Placental Matrix-Derived Mesenchymal Stem Cells Into the Penis to Treat the Symptoms of Mild to Moderate Erectile Dysfunction
Prospective, open-label, non-randomized, study to be conducted at a single center. Ten subjects will undergo an injection of Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs) into the penis for the treatment of mild to moderate erectile dysfunction. Follow up visits will be conducted at 6 weeks, 3 months, 6 months, and 12 months. Subjects will be evaluated for re-injection beginning at 3 months. Eligibility is determined by the clinician based on patient reported treatment satisfaction.
An estimated 18 million men in the United States are diagnosed with Erectile Dysfunction
(ED). ED is a physical condition triggered by a man's mental, emotional, and medical state.
Defined by the repeated and consistent problem sustaining an erection suitable for sexual
intercourse; ED can lead to performance anxiety and depression as a result partners of men
with ED also suffer emotional and psychological effects.
Lifestyle, smoking, medical conditions such as diabetes, hypertension and vascular problems,
prostate cancer and medication side effects all can contribute to the cause of ED.
Conservative treatments can begin with lifestyle change; natural remedies include the use of
herbs such as L-Arginine, Ginko, Zinc, and Yohimbe. Prescription medications known as
phosphodiesterase type 5 inhibitors are often used but are costly. other therapies involve
the penis pump/penis vacuum, penile implants that offer a permanent solution and surgery to
improve the blood flow to the penis can improve erections.
Mesenchymal stem cells (MSCs) have been used for a variety of medical treatments to repair
and regenerate acute and chronically damaged tissues. These cells have the potential to
repair human tissue by forming cells of mesenchymal origin, such as cartilage, bone, fat,
muscle, and blood vessels. Most research has focused on bone marrow derived stem cells (BMC)
however the process for harvesting the cells is invasive, painful, and yields a low cell
count. The human placenta offers an alternative source form MSCs. Placental Matrix-Derived
Mesenchymal Stem Cells (PMD-MSCs) are compromised of a novel cellular repair matrix derived
from placental mesenchyme. Mesenchyme is the meshwork of embryonic connective tissue in the
mesoderm, from which are formed the muscular and connective tissues of the body and also the
blood vessels. PMD-MSCs provide the extracellular matrix viable mesenchymal stem cells
(MSCs) that coordinate the tissue repair process, regenerative growth factors, and
anti-inflammatory cytokines required to regenerate the damaged vasculature of the penile
corpora.
Injecting PMD-MSCs into the penile corpora to replace the dysfunctional or dead cells is an
intriguing option for cell-based treatment for ED. The research proposed here will establish
the safety and feasibility of utilizing intracavernosal injections of PMD-MSCs to treat
Erectile Dysfunction.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05366504 -
LiST Plus PRP Injection Therapy vs LiST Monotherapy for ED Treatment
|
Phase 2/Phase 3 | |
Recruiting |
NCT02573805 -
the Diagnostic Value of Rigiscan Test (Nocturnal Penile Tumescence and Rigidity, NPTR) in Chinese Males
|
N/A | |
Recruiting |
NCT02745808 -
Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
Withdrawn |
NCT02579148 -
Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
Withdrawn |
NCT01967251 -
Efficacy, Safety and Dose-response of Udenafil in Patients With Benign Prostatic Hyperplasia and Erectile Dysfunction
|
Phase 2 | |
Recruiting |
NCT02225548 -
Sagene 2014 - Parkinson's Disease and Erectile Dysfunction
|
Phase 4 | |
Completed |
NCT02587988 -
Trial to Evaluate the Efficacy and Safety of HCP1302
|
Phase 3 | |
Completed |
NCT02945462 -
Bone Marrow Mesenchymal Stem Cells in Erectile Dysfunction (ED)
|
Phase 1 | |
Completed |
NCT01937871 -
A Study of Tadalafil in Men With Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED)
|
Phase 3 | |
Completed |
NCT01698684 -
Research Evaluating a PDE5 Inhibitor for Erectile Dysfunction
|
Phase 4 | |
Not yet recruiting |
NCT01321489 -
A Study to Evaluate a Possible Superiority Expressed by the Faster Onset of Action and the Efficacy and Safety of Sildenafil Citrate 20mg Sublingual Tablet in the Treatment of Erectile Dysfunction of Different Etiologies
|
Phase 3 | |
Terminated |
NCT01262833 -
Pudendal Assessment in Erectile Dysfunction
|
N/A | |
Completed |
NCT02226237 -
Effectiveness of Physiotherapy to Treat the Urinary Incontinence and Erectile Dysfunction Post Retropubic Prostatectomy
|
N/A | |
Completed |
NCT01230541 -
Effect of Udenafil on Spermatogenesis
|
Phase 1 | |
Completed |
NCT01037218 -
Treatment of Erectile Dysfunction II
|
Phase 3 | |
Completed |
NCT01037244 -
Treatment of Erectile Dysfunction I
|
Phase 3 | |
Recruiting |
NCT00313898 -
Effect of Sildenafil on Quality of Sexual Life in Mild to Normally Sexually Functioning Males
|
Phase 4 | |
Completed |
NCT00667979 -
Evaluating the Efficacy of Vardenafil in Subjects With Erectile Dysfunction (ED) Administered 12, 18 or 24 Hours Prior to Intercourse
|
Phase 4 | |
Completed |
NCT00663728 -
Assessment of Duration of Erection With Vardenafil 10 mg
|
Phase 4 | |
Completed |
NCT00421083 -
Efficacy and Safety of Tadalafil in Subjects With Erectile Dysfunction Caused by Spinal Cord Injury
|
Phase 3 |